NEW YORK (GenomeWeb News) – The National Cancer Institute is seeking clinically annotated biospecimens for a number of cancer types that it will use in The Cancer Genome Atlas (TCGA) program, a collaboration with the National Human Genome Research Institute which aims to study at least 20 cancers over the next five years.
NCI expects that it will need more than 40,000 biosamples to supply TCGA over the coming years to study all of these cancer varieties.
NCI currently has five different requests for quotations available for businesses or entities that can provide high-quality and well-annotated biospecimens that can be used in genomic studies.
The goal of the open bidding program, which has several different due dates depending on the RFQ, is to supply biosamples for a variety of cancer types, including glioblastoma multiforme, lung squamous cell carcinoma, colon cancer, stomach cancer, breast cancers, other cancer types that are currently not identified, and a number of other specific cancer types.
NCI also expects to spend up to $90 million over the next five years for between four and 10 new centers to support TCGA program.
The genome atlas project is an effort to study the entire spectrum of genomic changes in cancer, specifically the comprehensive analysis of DNA copy number changes, including large and small scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in tumor tissue and germline DNA.